September 11, 2025 – The results of the Phase III clinical trial for rifasutenizol (TNP-2198), a global first-in-class drug developed by TenNor Therapeutics for the treatment of Helicobacter pylori infection, have been published online in the prestigious international journal The Lancet Infectious Diseases.

Rifasutenizol is the first new molecular entity (NME) drug specifically developed for H. pylori infection since the bacterium’s discovery. Its multi-target synergistic mechanism is expected to overcome the resistance issues associated with traditional antibiotics, offering a novel treatment option for patients with H. pylori infection.

This Phase III clinical trial was a multicenter, randomized, double-blind, positive-controlled study conducted in China, led by Professor Liya Zhou from Peking University Third Hospital, and involving 40 clinical centers nationwide. The results demonstrated that the TNP-2198-based triple therapy showed multiple advantages over the current standard bismuth-based quadruple therapy.

As the world’s first antibacterial drug specifically developed for H. pylori infection, rifasutenizol provides a significant tool to address the growing challenge of antibiotic resistance. The triple therapy centered on TNP-2198 also has the potential to become a first-line treatment for H. pylori infection.

Article link: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00438-4/abstract

Media Contact:

Phone: +86 512-8686-1986

Email: info@tennorx.com or may.yang@h-advisors.global

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com